epinastine has been researched along with Hyperemia in 3 studies
epinastine: RN given refers parent cpd
epinastine : A benzazepine that is 6,11-dihydro-5H-dibenzo[b,e]azepine in which the azepine ring is fused to the e side of 4,5-dihydro-1H-imidazol-2-amine.
Hyperemia: The presence of an increased amount of blood in a body part or an organ leading to congestion or engorgement of blood vessels. Hyperemia can be due to increase of blood flow into the area (active or arterial), or due to obstruction of outflow of blood from the area (passive or venous).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Epinastine is effective and safe for the treatment of allergic conjunctivitis." | 9.19 | Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge. ( Fujishima, H; Ohashi, Y; Takamura, E, 2014) |
| "Epinastine is effective and safe for the treatment of allergic conjunctivitis." | 5.19 | Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge. ( Fujishima, H; Ohashi, Y; Takamura, E, 2014) |
| "Signs of allergic conjunctivitis generally were reduced most by a combination of a CC in combination with ATs or EH." | 2.79 | Effectiveness of nonpharmacologic treatments for acute seasonal allergic conjunctivitis. ( Bilkhu, PS; Kennedy, R; Naroo, SA; Robertson, L; Wolffsohn, JS, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ben-Eli, H | 1 |
| Solomon, A | 1 |
| Bilkhu, PS | 1 |
| Wolffsohn, JS | 1 |
| Naroo, SA | 1 |
| Robertson, L | 1 |
| Kennedy, R | 1 |
| Fujishima, H | 1 |
| Ohashi, Y | 1 |
| Takamura, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-masked, Comparison Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis - Phase 3, Confirmatory Study -[NCT01363700] | Phase 3 | 87 participants (Actual) | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean palpebral and bulbar conjunctiva hyperemia was assessed by the investigator at 5, 10, and 20 min post challenge and graded on a 4 points scale of 0-3 (0=none and 3= extremely severe). Total hyperemia score is defined as the sum of the palpebral and bulbar conjunctiva scores.~The endpoint used the average score of three time points (5, 10, and 20 minutes) after allergen challenge ." (NCT01363700)
Timeframe: Visit 7 (5, 10, and 20 minutes post-CAC)
| Intervention | score (Mean) |
|---|---|
| Epinastine (DE-114) Ophthalmic Solution | 2.4 |
| Olopatadine Ophthalmic Solution | 2.7 |
| Placebo Ophthalmic Solution | 3.7 |
"A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean palpebral and bulbar conjunctiva hyperemia was assessed by the investigator at 5, 10, and 20 min post challenge and graded on a 4 points scale of 0-3 (0=none and 3= extremely severe). Total hyperemia score is defined as the sum of the palpebral and bulbar conjunctiva scores. Count unit was defined each eye.~The endpoint used the average score of three time points (5, 10, and 20 minutes) after allergen challenge ." (NCT01363700)
Timeframe: Visit 5 (5, 10, and 20 minutes post-CAC)
| Intervention | score (Mean) |
|---|---|
| Epinastine (DE-114) Ophthalmic Solution | 2.7 |
| Placebo Ophthalmic Solution | 4.1 |
"A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean ocular itching score was assessed by the subject at 3, 5, and 10 min post challenge on a 5 points scale of 0-4 where 0=no itching and 4=incapacitating itch.~The endpoint used the average score of three time points (3, 5, and 10 minutes) after allergen challenge ." (NCT01363700)
Timeframe: Visit 7 (3, 5, and 10 minutes post-CAC)
| Intervention | score (Mean) |
|---|---|
| Epinastine (DE-114) Ophthalmic Solution | 0.2 |
| Olopatadine Ophthalmic Solution | 0.2 |
| Placebo Ophthalmic Solution | 1.5 |
"A conjunctivitis allergic challenge (CAC) was performed 4 hours after drop instillation. Mean ocular itching score was assessed by the subject at 3, 5, and 10 min post challenge and graded on a 5 points scale of 0-4 where 0=no itching and 4=incapacitating itch. Count unit was defined each eye.~The endpoint used the average score of three time points (3, 5, and 10 minutes) after allergen challenge ." (NCT01363700)
Timeframe: Visit 5 (3, 5, and 10 minutes post-CAC)
| Intervention | score (Mean) |
|---|---|
| Epinastine (DE-114) Ophthalmic Solution | 0.4 |
| Placebo Ophthalmic Solution | 1.7 |
1 review available for epinastine and Hyperemia
| Article | Year |
|---|---|
Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends.
Topics: Administration, Ophthalmic; Anti-Allergic Agents; Benzazepines; Conjunctivitis, Allergic; Cromolyn S | 2018 |
2 trials available for epinastine and Hyperemia
| Article | Year |
|---|---|
Effectiveness of nonpharmacologic treatments for acute seasonal allergic conjunctivitis.
Topics: Acute Disease; Adult; Aged; Allergens; Combined Modality Therapy; Conjunctiva; Conjunctivitis, Aller | 2014 |
Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
Topics: Adult; Allergens; Anti-Allergic Agents; Cedrus; Conjunctiva; Conjunctivitis, Allergic; Dibenzazepine | 2014 |